EKO / TSX Venture Exchange
MONTREAL, June 18 /CNW Telbec/ - Noveko International Inc. ("Noveko" or
"the Company") is pleased to announce the appointment of the Honourable Pierre
Marc Johnson as director of the Company.
"It is with enthusiasm and pride that we welcome Pierre Marc Johnson as
director of Noveko. In joining our Board of Directors, Mr. Johnson brings
diversified experience and exceptional expertise in international trade,
negotiations and partnerships as well as health law. As Noveko continues to
expand and broaden its markets, Mr. Johnson's strategic advice will be most
valuable for our Group's global development and growth," said André Leroux,
Chairman of the Board and Chief Executive Officer of Noveko.
A former Premier of Quebec, Pierre Marc Johnson, lawyer and physician,
has since 1996 been of counsel to Heenan Blaikie, where he acts as lead
counsel and strategic adviser to international partnerships and foreign
investments with respect to new information technologies, entertainment, real
estate and financial products. Mr. Johnson has extensive experience in
international negotiations with the United Nations on environmental and
development issues. He has advised the Commission for Environmental
Cooperation (CEC), an international organization created by Canada, Mexico and
the United States under the North American Agreement on Environmental
Cooperation (NAAEC). Mr. Johnson has also penned numerous essays and articles
on international trade, globalization and the environment. He notably sits on
the ACE Aviation Holdings Corporation and Air Canada boards. He also chairs
the foresight committee of the Veolia Institute for the Environment of Paris
and is Chairman of the Board of the Quartier de la Santé (Health District
Corporation), a Montreal-based organization that fosters diagnostic and
Mr. Johnson has an honorary doctorate from Université Claude Bernard
Lyon I, France, He is a Fellow of the Royal Society of Canada, and a Grand
Officier de l'Ordre de la Pléiade.
The members of Noveko's Board of Directors have approved, effective
today, June 18, 2008, the grant of 200,000 stock options to Mr. Johnson,
entitling him to acquire Class A shares at the price of $3.95, representing
the closing price of the Class A shares on June 17, 2008. This grant of stock
options is implemented pursuant to the terms of the Stock Option Plan of the
Noveko International Inc. is a public holding company. Currently, its
operating subsidiaries are S.A.S. ECM, Noveko Inc., Laboratoire SyMa Inc.,
Bolduc Leroux Inc. and Magnum Pharmaceutics Inc. ECM specializes in portable
real-time ultrasound scanners for veterinary and human medicine. Noveko Inc.
develops biomedical and environmental products derived from its patented
antimicrobial filtration technology (Noveko(TM) antimicrobial face masks and
air filters). SyMa specializes in sanitizers, sold under the Azuro(TM) brand.
BLI is involved in the custom processing and distribution of steel products
based on client specifications. Magnum acts as a manufacturer sales agent for
the Noveko Group's biomedical and environmental products and sanitizers and
for other manufacturers.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, Noveko
International Inc., (514) 344-3030; http://www.noveko.com